- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Macitentan 10 mg, Macitentan 37.5 mg, Macitentan 75 mg, Placebo
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 935 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 43
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 35 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 43
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Crohn Disease
- Interventions
- Icotrokinra, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,092 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 60
- States / cities
- Chandler, Arizona • Litchfield Park, Arizona • Scottsdale, Arizona + 48 more
- Conditions
- Amyotrophic Lateral Sclerosis, ALS
- Interventions
- Placebo, Ravulizumab
- Drug · Biological
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 382 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 34
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Loma Linda, California + 27 more
- Conditions
- Hypertension, Vascular Diseases, Cardiovascular Diseases
- Interventions
- MINT-TLC, Control Condition
- Behavioral
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 251 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Colitis, Ulcerative
- Interventions
- Guselkumab, Golimumab, JNJ-78934804, Placebo
- Biological · Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 577 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 63
- States / cities
- Arcadia, California • Coronado, California • Lancaster, California + 54 more
- Conditions
- Crohn's Disease
- Interventions
- Guselkumab, Golimumab, JNJ-78934804, Placebo
- Biological · Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 703 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 90
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 79 more
- Conditions
- Crohn's Disease
- Interventions
- Risankizumab
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Oakland, California + 8 more
- Conditions
- Seizures
- Interventions
- Placebo, CVL-865
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 37
- States / cities
- Little Rock, Arkansas • Downey, California • Loma Linda, California + 33 more
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Interventions
- erlotinib hydrochloride, quinacrine dihydrochloride - Escalation dose, laboratory biomarker analysis, pharmacological study, quinacrine dihydrochloride - Extension dose
- Drug · Other
- Lead sponsor
- Neelesh Sharma MD PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Fistulizing Crohns Disease, Perianal Crohns Disease
- Interventions
- Guselkumab, Placebo
- Drug
- Lead sponsor
- Janssen-Cilag Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 288 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • New Haven, Connecticut • Miami, Florida + 12 more
- Conditions
- Chronic Severe Plaque-type Psoriasis
- Interventions
- Experimental : Secukinumab low dose, Experimental: Secukinumab high dose, Placebo Comparator: Secukinumab Placebo, Active Comparator: Etanercept
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Locally Advanced or Metastatic Urothelial Carcinoma
- Interventions
- Avelumab, Sacituzumab Govitecan (SG), M6223, NKTR-255, JB100
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 256 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 8
- States / cities
- Coeur d'Alene, Idaho • Kansas City, Kansas • Baltimore, Maryland + 4 more
- Conditions
- Infection, Human Immunodeficiency Virus, HIV Infections
- Interventions
- CAB Oral Tablets, CAB LA, ABC/3TC Oral tablets, RPV Oral Tablets, HAART, RPV
- Drug · Other
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 309 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2023
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 12 more
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Benralizumab, Placebo and Benralizumab
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 12
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Mission Viejo, California + 8 more
- Conditions
- HIV Infections
- Interventions
- Cabotegravir Tablets, Cabotegravir Injectable Suspension (CAB LA), Rilpivirine Tablets, Rilpivirine Injectable Suspension (RPV LA), BIKTARVY Tablets (BIK)
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 687 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 41
- States / cities
- Bakersfield, California • Beverly Hills, California • Los Angeles, California + 32 more
- Conditions
- Obesity Prevention, Weight Change, Weight Loss, Weight Loss Maintenance
- Interventions
- Reduced Food Variety (RFV), Home-based Resistance Training (HBRT), Buddy Training and Support (BTS), Acceptance and Commitment (ACT) Workshops
- Behavioral
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 544 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Ulcerative Colitis (UC)
- Interventions
- TD-1473 Dose A, TD-1473 Dose B, TD-1473 Dose C, Placebo
- Drug
- Lead sponsor
- Theravance Biopharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 239 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 38
- States / cities
- Chula Vista, California • La Jolla, California • Lancaster, California + 34 more
- Conditions
- Arthritis, Psoriatic
- Interventions
- Guselkumab, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,054 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Flagstaff, Arizona • Glendale, Arizona + 20 more
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- dimethyl fumarate, Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 19 Years to 58 Years
- Enrollment
- 1,736 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2019
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 44 more
- Conditions
- Mantle Cell Lymphoma
- Interventions
- Zanubrutinib, Tafasitamab
- Drug
- Lead sponsor
- Alvaro Alencar, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Atopic Dermatitis
- Interventions
- Tralokinumab, Placebo
- Drug
- Lead sponsor
- LEO Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 802 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 44
- States / cities
- Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 37 more
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Extended-release Guanfacine Hydrochloride, Atomoxetine Hydrochloride, Placebo Comparator
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 338 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 11
- States / cities
- San Diego, California • Maitland, Florida • Atlanta, Georgia + 8 more
- Conditions
- Anemia
- Interventions
- Methoxy Polyethylene Glycol-Epoetin Beta, Epoetin alfa, Epoetin beta, Darbepoetin alfa
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,228 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 83
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 69 more
- Conditions
- Early Parkinson Disease (Early PD)
- Interventions
- Pramipexol Extended Release, Pramipexol Immediate Release, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 539 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 16
- States / cities
- Gilbert, Arizona • Sun City, Arizona • La Jolla, California + 13 more